BMS isn’t the only firm trying to use degraders to tackle sickle cell disease. Novartis has a Wiz-targeting glue degrader, ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
The latest announcement is out from Beam Therapeutics ( (BEAM) ).
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Beam Therapeutics (BEAM) announced new data for its Engineered Stem Cell Antibody Evasion, or ESCAPE, conditioning platform.
Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Hemagglutination would be positive for maternal cells that have been bound with ... Kleihauer-Betke acid elution tes 1 Fetal hemoglobin resists release (or elution) from its RBC under acid ...
Only one quarter of patients living with sickle cell disease are prescribed disease modifying therapies, particularly newer ...